Roche has boosted its production from several hundred thousand doses to more than a million, in hopes that it would be able to quickly supply the medicine should the trials show positive results.
In the COVACTA trial Roche sought to measure Actemra's impact based on how many patients advanced to needing a mechanical ventilator or died from Covid-19, compared to standard treatments.
Although the drug reduced the time it took to discharge patients by an average of eight days, this was not considered significant as the main goal was not met.
So far, Gilead Science's remdesivir been shown by studies to help speed up recovery times for Covid-19 patients, while the older generic steroid dexamethasone in a UK-led trial reduced death rates by around a third among those with the most severe cases of infection.